{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:42:28Z","timestamp":1790934148129,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T00:00:00Z","timestamp":1291075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1038\/nrendo.2010.196","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T12:06:42Z","timestamp":1291118802000},"page":"43-53","source":"Crossref","is-referenced-by-count":107,"title":["Testicular germ cell tumors: pathogenesis, diagnosis and treatment"],"prefix":"10.1038","volume":"7","author":[{"given":"Christian","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,30]]},"reference":[{"key":"BFnrendo2010196_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJM199707243370406","volume":"337","author":"GJ Bosl","year":"1997","unstructured":"Bosl, G. J. & Motzer, R. J. Testicular germ-cell cancer. N. Engl. J. Med. 337, 242\u2013253 (1997).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010196_CR2","first-page":"250","volume-title":"WHO Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs","author":"JN Eble","year":"2004","unstructured":"Eble, J. N., Sauter, G., Epstein, J. I. & Sesterhenn, I. A. (eds) WHO Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs Ch. 4, 250\u2013262 (IARC Press, Lyon, 2004)."},{"key":"BFnrendo2010196_CR3","first-page":"304","volume":"4","author":"TM Ulbright","year":"1987","unstructured":"Ulbright, T. M. & Roth, L. M. Recent developments in the pathology of germ cell tumors. Semin. Diagn. Pathol. 4, 304\u2013319 (1987).","journal-title":"Semin. Diagn. Pathol."},{"issue":"Suppl. 2","key":"BFnrendo2010196_CR4","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1038\/modpathol.3800310","volume":"18","author":"TM Ulbright","year":"2005","unstructured":"Ulbright, T. M. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod. Pathol. 18 (Suppl. 2), S61\u2013S79 (2005).","journal-title":"Mod. Pathol."},{"key":"BFnrendo2010196_CR5","volume-title":"SEER Cancer Statistics Review, 1975\u20132006","author":"MJ Horner","year":"2009","unstructured":"Horner, M. J.  et al. SEER Cancer Statistics Review, 1975\u20132006, National Cancer Institute, Bethesda\n                    [online]\n                    \n                  , (2009)."},{"key":"BFnrendo2010196_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cncr.11054","volume":"97","author":"KA McGlynn","year":"2003","unstructured":"McGlynn, K. A.  et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97, 63\u201370 (2003).","journal-title":"Cancer"},{"key":"BFnrendo2010196_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ijc.21032","volume":"116","author":"MJ Garner","year":"2005","unstructured":"Garner, M. J., Turner, M. C., Ghadirian, P. & Krewski, D. Epidemiology of testicular cancer: an overview. Int. J. Cancer 116, 331\u2013339 (2005).","journal-title":"Int. J. Cancer"},{"key":"BFnrendo2010196_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/jnci\/djn101","volume":"100","author":"KA McGlynn","year":"2008","unstructured":"McGlynn, K. A.  et al. Persistent organochlorine pesticides and risk of testicular germ cell tumors. J. Natl Cancer Inst. 100, 663\u2013671 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrendo2010196_CR9","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/j.1464-410X.2009.08855.x","volume":"104","author":"JE Korkola","year":"2009","unstructured":"Korkola, J. E., Houldsworth, J., Bosl, G. J. & Chaganti, R. S. Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin. BJU Int. 104, 1334\u20131338 (2009).","journal-title":"BJU Int."},{"key":"BFnrendo2010196_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/ng.393","volume":"41","author":"PA Kanetsky","year":"2009","unstructured":"Kanetsky, P. A.  et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat. Genet. 41, 811\u2013815 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrendo2010196_CR11","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1200\/JCO.2008.20.0386","volume":"27","author":"JE Korkola","year":"2009","unstructured":"Korkola, J. E.  et al. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J. Clin. Oncol. 27, 5240\u20135247 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.eururo.2007.12.024","volume":"53","author":"S Krege","year":"2008","unstructured":"Krege, S.  et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur. Urol. 53, 478\u2013496 (2008).","journal-title":"Eur. Urol."},{"key":"BFnrendo2010196_CR13","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.1996.14.12.3126","volume":"14","author":"KP Dieckmann","year":"1996","unstructured":"Dieckmann, K. P. & Loy, V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J. Clin. Oncol. 14, 3126\u20133132 (1996).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR14","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2004.07.188","volume":"22","author":"M De Santis","year":"2004","unstructured":"De Santis, M.  et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J. Clin. Oncol. 22, 1034\u20131039 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.eururo.2007.12.025","volume":"53","author":"S Krege","year":"2008","unstructured":"Krege, S.  et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur. Urol. 53, 497\u2013513 (2008).","journal-title":"Eur. Urol."},{"key":"BFnrendo2010196_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/annonc\/mdi175","volume":"16","author":"CE Hoei-Hansen","year":"2005","unstructured":"Hoei-Hansen, C. E., Rajpert-De Meyts, E., Daugaard, G. & Skakkebaek, N. E. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann. Oncol. 16, 863\u2013868 (2005).","journal-title":"Ann. Oncol."},{"key":"BFnrendo2010196_CR17","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1136\/bmj.293.6559.1398","volume":"293","author":"H von der Maase","year":"1986","unstructured":"von der Maase, H.  et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br. Med. J. (Clin. Res. Ed.) 293, 1398\u20131401 (1986).","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"BFnrendo2010196_CR18","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0022-5347(01)62535-7","volume":"160","author":"SJ Harland","year":"1998","unstructured":"Harland, S. J.  et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J. Urol. 160, 1353\u20131357 (1998).","journal-title":"J. Urol."},{"key":"BFnrendo2010196_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0167-8140(92)90015-M","volume":"25","author":"YC Bayens","year":"1992","unstructured":"Bayens, Y. C., Helle, P. A., Van Putten, W. L. & Mali, S. P. Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. Radiother. Oncol. 25, 97\u2013102 (1992).","journal-title":"Radiother. Oncol."},{"key":"BFnrendo2010196_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0936-6555(98)80007-1","volume":"10","author":"JM Coleman","year":"1998","unstructured":"Coleman, J. M., Coleman, R. E., Turner, A. R., Radstone, C. R. & Champion, A. E. The management and clinical course of testicular seminoma: 15 years' experience at a single institution. Clin. Oncol. (R. Coll. Radiol.) 10, 237\u2013241 (1998).","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"BFnrendo2010196_CR21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.2005.08.003","volume":"23","author":"WG Jones","year":"2005","unstructured":"Jones, W. G.  et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J. Clin. Oncol. 23, 1200\u20131208 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1464-410X.2003.04273.x","volume":"92","author":"R Santoni","year":"2003","unstructured":"Santoni, R.  et al. Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only. BJU Int. 92, 47\u201352 (2003).","journal-title":"BJU Int."},{"key":"BFnrendo2010196_CR23","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO.1995.13.9.2255","volume":"13","author":"P Warde","year":"1995","unstructured":"Warde, P.  et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J. Clin. Oncol. 13, 2255\u20132262 (1995).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.1999.17.4.1146","volume":"17","author":"SD Foss\u00e5","year":"1999","unstructured":"Foss\u00e5, S. D.  et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J. Clin. Oncol. 17, 1146 (1999).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR25","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/jnci\/dji278","volume":"97","author":"LB Travis","year":"2005","unstructured":"Travis, L. B.  et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1354\u20131365 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrendo2010196_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(05)66984-X","volume":"366","author":"RT Oliver","year":"2005","unstructured":"Oliver, R. T.  et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366, 293\u2013300 (2005).","journal-title":"Lancet"},{"key":"BFnrendo2010196_CR27","first-page":"1637","volume":"9","author":"P Chung","year":"2002","unstructured":"Chung, P.  et al. Surveillance in stage I testicular seminoma\u2014risk of late relapse. Can. J. Urol. 9, 1637\u20131640 (2002).","journal-title":"Can. J. Urol."},{"key":"BFnrendo2010196_CR28","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2002.01.038","volume":"20","author":"P Warde","year":"2002","unstructured":"Warde, P.  et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol. 20, 4448\u20134452 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1034\/j.1600-0463.2003.11101111.x","volume":"111","author":"G Daugaard","year":"2003","unstructured":"Daugaard, G., Petersen, P. M. & R\u00f8rth, M. Surveillance in stage I testicular cancer. APMIS 111, 76\u201383 (2003).","journal-title":"APMIS"},{"key":"BFnrendo2010196_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S0936-6555(05)81100-8","volume":"4","author":"S Ramakrishnan","year":"1992","unstructured":"Ramakrishnan, S., Champion, A. E., Dorreen, M. S. & Fox, M. Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy? Clin. Oncol. (R. Coll. Radiol.) 4, 284\u2013286 (1992).","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"BFnrendo2010196_CR31","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.2003.07.169","volume":"21","author":"P Albers","year":"2003","unstructured":"Albers, P.  et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J. Clin. Oncol. 21, 1505\u20131512 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR32","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1200\/JCO.1996.14.4.1106","volume":"14","author":"MH Cullen","year":"1996","unstructured":"Cullen, M. H.  et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol. 14, 1106\u20131113 (1996).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1159\/000474650","volume":"23","author":"UE Studer","year":"1993","unstructured":"Studer, U. E.  et al. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur. Urol. 23, 444\u2013449 (1993).","journal-title":"Eur. Urol."},{"key":"BFnrendo2010196_CR34","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","volume":"25","author":"AW van den Belt-Dusebout","year":"2007","unstructured":"van den Belt-Dusebout, A. W.  et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370\u20134378 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1200\/JCO.2005.02.7193","volume":"24","author":"AW van den Belt-Dusebout","year":"2006","unstructured":"van den Belt-Dusebout, A. W.  et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 24, 467\u2013475 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR36","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1200\/JCO.2007.12.0899","volume":"26","author":"P Albers","year":"2008","unstructured":"Albers, P.  et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01\/94 by the German Testicular Cancer Study Group. J. Clin. Oncol. 26, 2966\u20132972 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR37","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","volume":"27","author":"T Tandstad","year":"2009","unstructured":"Tandstad, T.  et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J. Clin. Oncol. 27, 2122\u20132128 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.juro.2007.08.172","volume":"179","author":"DH Westermann","year":"2008","unstructured":"Westermann, D. H.  et al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J. Urol. 179, 163\u2013166 (2008).","journal-title":"J. Urol."},{"key":"BFnrendo2010196_CR39","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.5489\/cuaj.815","volume":"4","author":"L Wood","year":"2010","unstructured":"Wood, L.  et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can. Urol. Assoc. J. 4, e19\u2013e38 (2010).","journal-title":"Can. Urol. Assoc. J."},{"key":"BFnrendo2010196_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00345-009-0453-6","volume":"27","author":"DM Kakiashvili","year":"2009","unstructured":"Kakiashvili, D. M., Zuniga, A. & Jewett, M. A. High risk NSGCT: case for surveillance. World J. Urol. 27, 441\u2013447 (2009).","journal-title":"World J. Urol."},{"key":"BFnrendo2010196_CR41","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1464-410X.2009.08858.x","volume":"104","author":"A Zuniga","year":"2009","unstructured":"Zuniga, A., Kakiashvili, D. & Jewett, M. A. Surveillance in stage I nonseminomatous germ cell tumours of the testis. BJU Int. 104, 1351\u20131356 (2009).","journal-title":"BJU Int."},{"key":"BFnrendo2010196_CR42","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO.2003.06.065","volume":"21","author":"J Classen","year":"2003","unstructured":"Classen, J.  et al. Radiotherapy for stages IIA\/B testicular seminoma: final report of a prospective multicenter clinical trial. J. Clin. Oncol. 21, 1101\u20131106 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0360-3016(97)00155-7","volume":"39","author":"H Schmidberger","year":"1997","unstructured":"Schmidberger, H.  et al. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int. J. Radiat. Oncol. Biol. Phys. 39, 321\u2013326 (1997).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrendo2010196_CR44","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1200\/JCO.2007.15.9103","volume":"26","author":"X Garcia-del-Muro","year":"2008","unstructured":"Garcia-del-Muro, X.  et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J. Clin. Oncol. 26, 5416\u20135421 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR45","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/j.1464-410X.2009.08867.x","volume":"104","author":"C Winter","year":"2009","unstructured":"Winter, C., Raman, J. D., Sheinfeld, J. & Albers, P. Retroperitoneal lymph node dissection after chemotherapy. BJU Int. 104, 1404\u20131412 (2009).","journal-title":"BJU Int."},{"key":"BFnrendo2010196_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00192276","volume":"12","author":"A Horwich","year":"1994","unstructured":"Horwich, A. & Stenning, S. Initial chemotherapy for stage II testicular non-seminoma. World J. Urol. 12, 148\u2013150 (1994).","journal-title":"World J. Urol."},{"key":"BFnrendo2010196_CR47","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1464-410X.1985.tb07050.x","volume":"57","author":"MJ Peckham","year":"1985","unstructured":"Peckham, M. J. & Hendry, W. F. Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy. Br. J. Urol. 57, 763\u2013768 (1985).","journal-title":"Br. J. Urol."},{"key":"BFnrendo2010196_CR48","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0022-5347(17)47654-3","volume":"134","author":"CJ Logothetis","year":"1985","unstructured":"Logothetis, C. J.  et al. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J. Urol. 134, 1127\u20131130 (1985).","journal-title":"J. Urol."},{"key":"BFnrendo2010196_CR49","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1200\/JCO.1994.12.2.368","volume":"12","author":"EJ Feuer","year":"1994","unstructured":"Feuer, E. J.  et al. After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J. Clin. Oncol. 12, 368\u2013377 (1994).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR50","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/bjc.1995.254","volume":"71","author":"R de Wit","year":"1995","unstructured":"de Wit, R.  et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br. J. Cancer 71, 1311\u20131314 (1995).","journal-title":"Br. J. Cancer"},{"key":"BFnrendo2010196_CR51","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1200\/JCO.2007.13.8461","volume":"26","author":"S Culine","year":"2008","unstructured":"Culine, S.  et al. Randomized trial comparing bleomycin\/etoposide\/cisplatin with alternating cisplatin\/cyclophosphamide\/doxorubicin and vinblastine\/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J. Clin. Oncol. 26, 421\u2013427 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR52","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith, T. J.  et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24, 3187\u20133205 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR53","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1056\/NEJMoa050078","volume":"353","author":"M Cullen","year":"2005","unstructured":"Cullen, M.  et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N. Engl. J. Med. 353, 988\u2013998 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2010196_CR54","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0959-8049(00)00137-4","volume":"36","author":"F Andr\u00e9","year":"2000","unstructured":"Andr\u00e9, F.  et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur. J. Cancer 36, 1389\u20131394 (2000).","journal-title":"Eur. J. Cancer"},{"key":"BFnrendo2010196_CR55","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.1997.15.7.2546","volume":"15","author":"RJ Motzer","year":"1997","unstructured":"Motzer, R. J.  et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J. Clin. Oncol. 15, 2546\u20132552 (1997).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR56","first-page":"400","volume":"22","author":"JT Hartmann","year":"2003","unstructured":"Hartmann, J. T., Bamberg, M. & Albers, P. Multidisciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin [abstract 1607]. Proc. Am. Soc. Clin. Oncol. 22, 400 (2003).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BFnrendo2010196_CR57","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ijrobp.2007.11.005","volume":"70","author":"DM Doyle","year":"2008","unstructured":"Doyle, D. M. & Einhorn, L. H. Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int. J. Radiat. Oncol. Biol. Phys. 70, 1361\u20131364 (2008).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrendo2010196_CR58","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.juro.2007.10.054","volume":"179","author":"S Hinz","year":"2008","unstructured":"Hinz, S.  et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J. Urol. 179, 936\u2013940 (2008).","journal-title":"J. Urol."},{"key":"BFnrendo2010196_CR59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1200\/JCO.2009.23.0714","volume":"28","author":"Y Ehrlich","year":"2010","unstructured":"Ehrlich, Y., Brames, M. J., Beck, S. D., Foster, R. S. & Einhorn, L. H. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J. Clin. Oncol. 28, 531\u2013536 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR60","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.2009.23.0755","volume":"28","author":"C Kollmannsberger","year":"2010","unstructured":"Kollmannsberger, C.  et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J. Clin. Oncol. 28, 537\u2013542 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR61","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1200\/JCO.1993.11.7.1294","volume":"11","author":"EP Fox","year":"1993","unstructured":"Fox, E. P.  et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J. Clin. Oncol. 11, 1294\u20131299 (1993).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. July 15","key":"BFnrendo2010196_CR62","first-page":"abstr. 4584","volume":"22","author":"A Flechon","year":"2004","unstructured":"Flechon, A., Tavernier, E., Meeus, P., Rivoire, M. & Droz, J.-P. Study of the conformity of post-chemotherapy retroperitoneal lymph-node dissection (RPLND) to standard recommendations in patients with testicular (T) and primary retroperitoneal (PR) non-seminomatous germ-cell tumor (NSGCT): impact on outcome. J. Clin. Oncol. (ASCO Meeting Abstracts) 22 (Suppl. July 15), abstr. 4584 (2004).","journal-title":"J. Clin. Oncol. (ASCO Meeting Abstracts)"},{"key":"BFnrendo2010196_CR63","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdm472","volume":"19","author":"K Fizazi","year":"2008","unstructured":"Fizazi, K.  et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann. Oncol. 19, 259\u2013264 (2008).","journal-title":"Ann. Oncol."},{"key":"BFnrendo2010196_CR64","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.2001.19.10.2647","volume":"19","author":"K Fizazi","year":"2001","unstructured":"Fizazi, K.  et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy\u2014results from an international study group. J. Clin. Oncol. 19, 2647\u20132657 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR65","first-page":"4513","volume":"28","author":"A Lorch","year":"2010","unstructured":"Lorch, A.  et al. Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. J. Clin. Oncol. (ASCO Meeting Abstracts) 28 (Suppl. May 20), abstr. 4513 (2010).","journal-title":"J. Clin. Oncol. (ASCO Meeting Abstracts)"},{"key":"BFnrendo2010196_CR66","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/annonc\/mdp366","volume":"21","author":"A Lorch","year":"2010","unstructured":"Lorch, A.  et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann. Oncol. 21, 820\u2013825 (2010).","journal-title":"Ann. Oncol."},{"key":"BFnrendo2010196_CR67","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1200\/JCO.2006.09.2148","volume":"25","author":"A Lorch","year":"2007","unstructured":"Lorch, A.  et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J. Clin. Oncol. 25, 2778\u20132784 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR68","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.1464-410X.2009.08868.x","volume":"104","author":"J Oldenburg","year":"2009","unstructured":"Oldenburg, J. & Foss\u00e5, S. D. Late relapse of nonseminomatous germ cell tumours. BJU Int. 104, 1413\u20131417 (2009).","journal-title":"BJU Int."},{"key":"BFnrendo2010196_CR69","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00345-009-0411-3","volume":"27","author":"J Oldenburg","year":"2009","unstructured":"Oldenburg, J., Wahlqvist, R. & Foss\u00e5, S. D. Late relapse of germ cell tumors. World J. Urol. 27, 493\u2013500 (2009).","journal-title":"World J. Urol."},{"key":"BFnrendo2010196_CR70","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","volume":"23","author":"GV Kondagunta","year":"2005","unstructured":"Kondagunta, G. V.  et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol. 23, 6549\u20136555 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR71","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/j.1464-410X.2009.08869.x","volume":"104","author":"SD Foss\u00e5","year":"2009","unstructured":"Foss\u00e5, S. D., Oldenburg, J. & Dahl, A. A. Short- and long-term morbidity after treatment for testicular cancer. BJU Int. 104, 1418\u20131422 (2009).","journal-title":"BJU Int."},{"key":"BFnrendo2010196_CR72","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1200\/JCO.2005.02.176","volume":"23","author":"J Nuver","year":"2005","unstructured":"Nuver, J.  et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J. Clin. Oncol. 23, 3718\u20133725 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR73","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2003.04.173","volume":"21","author":"RA Huddart","year":"2003","unstructured":"Huddart, R. A.  et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21, 1513\u20131523 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR74","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jnci\/djk111","volume":"99","author":"SD Foss\u00e5","year":"2007","unstructured":"Foss\u00e5, S. D.  et al. Noncancer causes of death in survivors of testicular cancer. J. Natl Cancer Inst. 99, 533\u2013544 (2007).","journal-title":"J. Natl Cancer Inst."},{"issue":"Suppl. 6","key":"BFnrendo2010196_CR75","first-page":"S3","volume":"6","author":"C Carnegie","year":"2004","unstructured":"Carnegie, C. Diagnosis of hypogonadism: clinical assessments and laboratory tests. Rev. Urol. 6 (Suppl. 6), S3\u2013S8 (2004).","journal-title":"Rev. Urol."},{"key":"BFnrendo2010196_CR76","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1200\/JCO.1997.15.1.239","volume":"15","author":"H Lampe","year":"1997","unstructured":"Lampe, H., Horwich, A., Norman, A., Nicholls, J. & Dearnaley, D. P. Fertility after chemotherapy for testicular germ cell cancers. J. Clin. Oncol. 15, 239\u2013245 (1997).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2010196_CR77","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/jnci\/dji339","volume":"97","author":"M Bryd\u00f8y","year":"2005","unstructured":"Bryd\u00f8y, M.  et al. Paternity following treatment for testicular cancer. J. Natl Cancer Inst. 97, 1580\u20131588 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrendo2010196_CR78","first-page":"2575","volume":"12","author":"DS Ernst","year":"2005","unstructured":"Ernst, D. S.  et al. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can. J. Urol. 12, 2575\u20132580 (2005).","journal-title":"Can. J. Urol."},{"key":"BFnrendo2010196_CR79","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00345-009-0431-z","volume":"27","author":"DR Feldman","year":"2009","unstructured":"Feldman, D. R. & Motzer, R. J. Good-risk-advanced germ cell tumors: historical perspective and current standards of care. World J. Urol. 27, 463\u2013470 (2009).","journal-title":"World J. Urol."},{"key":"BFnrendo2010196_CR80","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/j.1464-410X.2007.06740.x","volume":"99","author":"B Shayegan","year":"2007","unstructured":"Shayegan, B.  et al. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. BJU Int. 99, 993\u2013997 (2007).","journal-title":"BJU Int."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.196","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2010.196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:34:48Z","timestamp":1684467288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2010.196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,30]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["BFnrendo2010196"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2010.196","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,30]]}}}